Review



flub dmab  (Harlan Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Harlan Laboratories flub dmab
    In vitro and in vivo expression of DNA-encoded monoclonal antibody <t>(DMAb)</t> constructs. a 293 T cells were transfected with <t>FluA</t> or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)
    Flub Dmab, supplied by Harlan Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flub+dmab/flub+dmab/pmc05627301-189-8-5
    Average 90 stars, based on 1 article reviews
    flub dmab - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections"

    Article Title: DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

    Journal: NPJ Vaccines

    doi: 10.1038/s41541-017-0020-x

    In vitro and in vivo expression of DNA-encoded monoclonal antibody (DMAb) constructs. a 293 T cells were transfected with FluA or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)
    Figure Legend Snippet: In vitro and in vivo expression of DNA-encoded monoclonal antibody (DMAb) constructs. a 293 T cells were transfected with FluA or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)

    Techniques Used: In Vitro, In Vivo, Expressing, Construct, Transfection, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Western Blot, Purification, Electroporation

    Serum FluA DMAb and FluB DMAb are functional. Functional assays performed with sera from BALB/c mice collected 5 days after treatment with 100–300 μg of FluA DMAb plasmid DNA ( a ) or FluB DMAb plasmid DNA ( b ) and ( c ). a ELISA binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza A HA proteins from Group 1 (H1, A/California/07/2009 H1N1; H2, A/Missouri/2006 H2N3; H5, A/Vietnam/1203/2004 H5N1; H6, A/teal/Hong Kong/W312/97 H6N1; H9, A/chicken/Hong Kong/G9/1997 H9N2) and Group 2 (H3, A/Perth/16/2009 H3N2; H7, A/Netherlands/219/2003 H7N7). b ELISA Binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza B HA proteins from the Yamagata (Yam B/Florida/4/2006) and Victoria (Vic B/Brisbane/60/2008) lineages. c Neutralization IC 50 values (reciprocal dilution) for individual mouse serum samples against influenza B viruses from the Yamagata (Yam virus B/Florida/4/2006) and Victoria (Vic virus B/Malaysia/2506/2004) lineages. ( n = 5 animals per group, mean ± SD)
    Figure Legend Snippet: Serum FluA DMAb and FluB DMAb are functional. Functional assays performed with sera from BALB/c mice collected 5 days after treatment with 100–300 μg of FluA DMAb plasmid DNA ( a ) or FluB DMAb plasmid DNA ( b ) and ( c ). a ELISA binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza A HA proteins from Group 1 (H1, A/California/07/2009 H1N1; H2, A/Missouri/2006 H2N3; H5, A/Vietnam/1203/2004 H5N1; H6, A/teal/Hong Kong/W312/97 H6N1; H9, A/chicken/Hong Kong/G9/1997 H9N2) and Group 2 (H3, A/Perth/16/2009 H3N2; H7, A/Netherlands/219/2003 H7N7). b ELISA Binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza B HA proteins from the Yamagata (Yam B/Florida/4/2006) and Victoria (Vic B/Brisbane/60/2008) lineages. c Neutralization IC 50 values (reciprocal dilution) for individual mouse serum samples against influenza B viruses from the Yamagata (Yam virus B/Florida/4/2006) and Victoria (Vic virus B/Malaysia/2506/2004) lineages. ( n = 5 animals per group, mean ± SD)

    Techniques Used: Functional Assay, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Binding Assay, Neutralization

    FluA DMAb protects mice from diverse lethal influenza A challenges. BALB/c mice were treated with FluA DMAb plasmid DNA ( closed symbols ) 4–5 days prior to intranasal infection with A/California/7/2009 H1N1 ( a–c ) or re-assorted rA/HongKong/8/68 × PR8 H3N1 ( d–f ). 1 day prior to infection, separate mice received 0.03–1 mg/kg FluA protein monoclonal antibody i.p. ( open symbols ). Mice treated with 300 μg irrelevant DMAb (DVSF-3) or 1 mg/kg non-specific protein monoclonal antibody (R347) served as controls. a , d Human IgG in mouse sera at the time of influenza infection. Dotted line indicates LOD. ( a n = 10 animals, d n = 5 animals per group, mean ± SD). b , e Kaplan–Meier survival curves of BALB/c mice challenged with influenza A ( n = 10 animals per group, * p ≤ 0.0001 FluA DMAb versus Control DMAb). c , f Weight of BALB/c mice following influenza A challenge. Dotted line indicates 25% maximum weight loss. ( n = 10 animals per group, mean ± SEM)
    Figure Legend Snippet: FluA DMAb protects mice from diverse lethal influenza A challenges. BALB/c mice were treated with FluA DMAb plasmid DNA ( closed symbols ) 4–5 days prior to intranasal infection with A/California/7/2009 H1N1 ( a–c ) or re-assorted rA/HongKong/8/68 × PR8 H3N1 ( d–f ). 1 day prior to infection, separate mice received 0.03–1 mg/kg FluA protein monoclonal antibody i.p. ( open symbols ). Mice treated with 300 μg irrelevant DMAb (DVSF-3) or 1 mg/kg non-specific protein monoclonal antibody (R347) served as controls. a , d Human IgG in mouse sera at the time of influenza infection. Dotted line indicates LOD. ( a n = 10 animals, d n = 5 animals per group, mean ± SD). b , e Kaplan–Meier survival curves of BALB/c mice challenged with influenza A ( n = 10 animals per group, * p ≤ 0.0001 FluA DMAb versus Control DMAb). c , f Weight of BALB/c mice following influenza A challenge. Dotted line indicates 25% maximum weight loss. ( n = 10 animals per group, mean ± SEM)

    Techniques Used: Plasmid Preparation, Infection

    Co-administration of FluA and FluB DMAb protects mice from lethal influenza A/B challenge and homologous re-challenge. BALB/c mice received both FluA and FluB DMAb. Separate mice were treated with both FluA plus FluB protein monoclonal antibody. Mice received initial infection with either influenza A/California/7/2009 or B/Florida/4/2006. a Total human IgG levels in mice sera at the time of infection ( n = 8 animals per group, mean ± SD). b Influenza A-specific and B-specific human IgG in mouse serum at the time of infection quantified by HA binding ELISA ( n = 8 animals per group, mean ± SD). c , d Kaplan–Meier survival curves following initial infection with A/California/07/2009 ( c ) or B/Florida/4/2006 ( d ) ( n = 10 animals per group, * p ≤ 0.0001 Flu DMAb versus control DMAb). e , f 28 days following initial infection, surviving mice received homologous influenza re-infection. Kaplan–Meier survival curves following re-infection, compared to mice receiving neither DMAb/IgG treatment nor initial infection (naïve). (Number of animals in each group are shown)
    Figure Legend Snippet: Co-administration of FluA and FluB DMAb protects mice from lethal influenza A/B challenge and homologous re-challenge. BALB/c mice received both FluA and FluB DMAb. Separate mice were treated with both FluA plus FluB protein monoclonal antibody. Mice received initial infection with either influenza A/California/7/2009 or B/Florida/4/2006. a Total human IgG levels in mice sera at the time of infection ( n = 8 animals per group, mean ± SD). b Influenza A-specific and B-specific human IgG in mouse serum at the time of infection quantified by HA binding ELISA ( n = 8 animals per group, mean ± SD). c , d Kaplan–Meier survival curves following initial infection with A/California/07/2009 ( c ) or B/Florida/4/2006 ( d ) ( n = 10 animals per group, * p ≤ 0.0001 Flu DMAb versus control DMAb). e , f 28 days following initial infection, surviving mice received homologous influenza re-infection. Kaplan–Meier survival curves following re-infection, compared to mice receiving neither DMAb/IgG treatment nor initial infection (naïve). (Number of animals in each group are shown)

    Techniques Used: Infection, Binding Assay, Enzyme-linked Immunosorbent Assay



    Similar Products

    flub dmab  (Harlan Laboratories)
    90
    Harlan Laboratories flub dmab
    In vitro and in vivo expression of DNA-encoded monoclonal antibody <t>(DMAb)</t> constructs. a 293 T cells were transfected with <t>FluA</t> or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)
    Flub Dmab, supplied by Harlan Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flub+dmab/flub+dmab/pmc05627301-189-8-5
    Average 90 stars, based on 1 article reviews
    flub dmab - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro and in vivo expression of DNA-encoded monoclonal antibody (DMAb) constructs. a 293 T cells were transfected with FluA or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)

    Journal: NPJ Vaccines

    Article Title: DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

    doi: 10.1038/s41541-017-0020-x

    Figure Lengend Snippet: In vitro and in vivo expression of DNA-encoded monoclonal antibody (DMAb) constructs. a 293 T cells were transfected with FluA or FluB DMAb plasmid constructs, or empty plasmid (pVax1). Human IgG expression in cell supernatants ( left ) and lysates ( right ) was quantified by ELISA. ( n = 3 biological replicates, mean ± SEM). b Western blot of human IgG heavy-chain and light-chain peptides in reduced DMAb-transfected 293 T cell supernatants (S) and lysates (L) ( left ), and purified protein monoclonal antibody FluA and FluB (IgG, right ). Samples derive from the same experiment and gels/blots were processed in parallel. c , d DMAb human IgG in CAnN.Cg- Foxn1 nu /Crl nude mouse sera after intramuscular electroporation (IM-EP) (Day 0) with 100–300 μg of FluA ( c ) or FluB ( d ) DMAb plasmid DNA. Sera were collected up to 35 days post electroporation in mice treated with 100 μg FluA DMAb, and up to 70 days in all other groups. ( n = 5 animals per group, mean ± SEM). e , f Levels of DMAb human IgG in BALB/c mouse sera 5 days post administration of 100–300 μg of FluA ( e ) or FluB ( f ) DMAb plasmid DNA. Dotted line indicates limit of detection (LOD). ( n = 5 animals per group, mean ± SEM)

    Article Snippet: Six- to eight-week-old BALB/c mice (Harlan Laboratories) received FluA DMAb, FluB DMAb, or an irrelevant control DMAb (DVSF-3, previously described) via IM-EP 4–5 days prior to infection.

    Techniques: In Vitro, In Vivo, Expressing, Construct, Transfection, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Western Blot, Purification, Electroporation

    Serum FluA DMAb and FluB DMAb are functional. Functional assays performed with sera from BALB/c mice collected 5 days after treatment with 100–300 μg of FluA DMAb plasmid DNA ( a ) or FluB DMAb plasmid DNA ( b ) and ( c ). a ELISA binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza A HA proteins from Group 1 (H1, A/California/07/2009 H1N1; H2, A/Missouri/2006 H2N3; H5, A/Vietnam/1203/2004 H5N1; H6, A/teal/Hong Kong/W312/97 H6N1; H9, A/chicken/Hong Kong/G9/1997 H9N2) and Group 2 (H3, A/Perth/16/2009 H3N2; H7, A/Netherlands/219/2003 H7N7). b ELISA Binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza B HA proteins from the Yamagata (Yam B/Florida/4/2006) and Victoria (Vic B/Brisbane/60/2008) lineages. c Neutralization IC 50 values (reciprocal dilution) for individual mouse serum samples against influenza B viruses from the Yamagata (Yam virus B/Florida/4/2006) and Victoria (Vic virus B/Malaysia/2506/2004) lineages. ( n = 5 animals per group, mean ± SD)

    Journal: NPJ Vaccines

    Article Title: DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

    doi: 10.1038/s41541-017-0020-x

    Figure Lengend Snippet: Serum FluA DMAb and FluB DMAb are functional. Functional assays performed with sera from BALB/c mice collected 5 days after treatment with 100–300 μg of FluA DMAb plasmid DNA ( a ) or FluB DMAb plasmid DNA ( b ) and ( c ). a ELISA binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza A HA proteins from Group 1 (H1, A/California/07/2009 H1N1; H2, A/Missouri/2006 H2N3; H5, A/Vietnam/1203/2004 H5N1; H6, A/teal/Hong Kong/W312/97 H6N1; H9, A/chicken/Hong Kong/G9/1997 H9N2) and Group 2 (H3, A/Perth/16/2009 H3N2; H7, A/Netherlands/219/2003 H7N7). b ELISA Binding EC 50 values (reciprocal dilution) for individual mouse serum samples to influenza B HA proteins from the Yamagata (Yam B/Florida/4/2006) and Victoria (Vic B/Brisbane/60/2008) lineages. c Neutralization IC 50 values (reciprocal dilution) for individual mouse serum samples against influenza B viruses from the Yamagata (Yam virus B/Florida/4/2006) and Victoria (Vic virus B/Malaysia/2506/2004) lineages. ( n = 5 animals per group, mean ± SD)

    Article Snippet: Six- to eight-week-old BALB/c mice (Harlan Laboratories) received FluA DMAb, FluB DMAb, or an irrelevant control DMAb (DVSF-3, previously described) via IM-EP 4–5 days prior to infection.

    Techniques: Functional Assay, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Binding Assay, Neutralization

    FluA DMAb protects mice from diverse lethal influenza A challenges. BALB/c mice were treated with FluA DMAb plasmid DNA ( closed symbols ) 4–5 days prior to intranasal infection with A/California/7/2009 H1N1 ( a–c ) or re-assorted rA/HongKong/8/68 × PR8 H3N1 ( d–f ). 1 day prior to infection, separate mice received 0.03–1 mg/kg FluA protein monoclonal antibody i.p. ( open symbols ). Mice treated with 300 μg irrelevant DMAb (DVSF-3) or 1 mg/kg non-specific protein monoclonal antibody (R347) served as controls. a , d Human IgG in mouse sera at the time of influenza infection. Dotted line indicates LOD. ( a n = 10 animals, d n = 5 animals per group, mean ± SD). b , e Kaplan–Meier survival curves of BALB/c mice challenged with influenza A ( n = 10 animals per group, * p ≤ 0.0001 FluA DMAb versus Control DMAb). c , f Weight of BALB/c mice following influenza A challenge. Dotted line indicates 25% maximum weight loss. ( n = 10 animals per group, mean ± SEM)

    Journal: NPJ Vaccines

    Article Title: DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

    doi: 10.1038/s41541-017-0020-x

    Figure Lengend Snippet: FluA DMAb protects mice from diverse lethal influenza A challenges. BALB/c mice were treated with FluA DMAb plasmid DNA ( closed symbols ) 4–5 days prior to intranasal infection with A/California/7/2009 H1N1 ( a–c ) or re-assorted rA/HongKong/8/68 × PR8 H3N1 ( d–f ). 1 day prior to infection, separate mice received 0.03–1 mg/kg FluA protein monoclonal antibody i.p. ( open symbols ). Mice treated with 300 μg irrelevant DMAb (DVSF-3) or 1 mg/kg non-specific protein monoclonal antibody (R347) served as controls. a , d Human IgG in mouse sera at the time of influenza infection. Dotted line indicates LOD. ( a n = 10 animals, d n = 5 animals per group, mean ± SD). b , e Kaplan–Meier survival curves of BALB/c mice challenged with influenza A ( n = 10 animals per group, * p ≤ 0.0001 FluA DMAb versus Control DMAb). c , f Weight of BALB/c mice following influenza A challenge. Dotted line indicates 25% maximum weight loss. ( n = 10 animals per group, mean ± SEM)

    Article Snippet: Six- to eight-week-old BALB/c mice (Harlan Laboratories) received FluA DMAb, FluB DMAb, or an irrelevant control DMAb (DVSF-3, previously described) via IM-EP 4–5 days prior to infection.

    Techniques: Plasmid Preparation, Infection

    Co-administration of FluA and FluB DMAb protects mice from lethal influenza A/B challenge and homologous re-challenge. BALB/c mice received both FluA and FluB DMAb. Separate mice were treated with both FluA plus FluB protein monoclonal antibody. Mice received initial infection with either influenza A/California/7/2009 or B/Florida/4/2006. a Total human IgG levels in mice sera at the time of infection ( n = 8 animals per group, mean ± SD). b Influenza A-specific and B-specific human IgG in mouse serum at the time of infection quantified by HA binding ELISA ( n = 8 animals per group, mean ± SD). c , d Kaplan–Meier survival curves following initial infection with A/California/07/2009 ( c ) or B/Florida/4/2006 ( d ) ( n = 10 animals per group, * p ≤ 0.0001 Flu DMAb versus control DMAb). e , f 28 days following initial infection, surviving mice received homologous influenza re-infection. Kaplan–Meier survival curves following re-infection, compared to mice receiving neither DMAb/IgG treatment nor initial infection (naïve). (Number of animals in each group are shown)

    Journal: NPJ Vaccines

    Article Title: DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

    doi: 10.1038/s41541-017-0020-x

    Figure Lengend Snippet: Co-administration of FluA and FluB DMAb protects mice from lethal influenza A/B challenge and homologous re-challenge. BALB/c mice received both FluA and FluB DMAb. Separate mice were treated with both FluA plus FluB protein monoclonal antibody. Mice received initial infection with either influenza A/California/7/2009 or B/Florida/4/2006. a Total human IgG levels in mice sera at the time of infection ( n = 8 animals per group, mean ± SD). b Influenza A-specific and B-specific human IgG in mouse serum at the time of infection quantified by HA binding ELISA ( n = 8 animals per group, mean ± SD). c , d Kaplan–Meier survival curves following initial infection with A/California/07/2009 ( c ) or B/Florida/4/2006 ( d ) ( n = 10 animals per group, * p ≤ 0.0001 Flu DMAb versus control DMAb). e , f 28 days following initial infection, surviving mice received homologous influenza re-infection. Kaplan–Meier survival curves following re-infection, compared to mice receiving neither DMAb/IgG treatment nor initial infection (naïve). (Number of animals in each group are shown)

    Article Snippet: Six- to eight-week-old BALB/c mice (Harlan Laboratories) received FluA DMAb, FluB DMAb, or an irrelevant control DMAb (DVSF-3, previously described) via IM-EP 4–5 days prior to infection.

    Techniques: Infection, Binding Assay, Enzyme-linked Immunosorbent Assay